SHR-A1811 Injection
Sponsors
Jiangsu HengRui Medicine Co., Ltd., Shengjing Hospital, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions
Advanced Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-PositiveRecurrent or Metastatic Breast CancerHR Positive/HER2 Low Breast CancerMetastatic Gastric CancerNon Small Cell Lung CancerRecurrent or Metastatic Cervical Cancer
Phase 2
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
RecruitingNCT06340230
Start: 2024-08-23End: 2031-02-28Target: 93Updated: 2024-12-04
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
RecruitingNCT07051486
Start: 2025-10-11End: 2026-08-31Target: 60Updated: 2025-11-17
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
RecruitingNCT07102901
Start: 2025-09-05End: 2027-12-31Target: 351Updated: 2025-09-10
Phase 3
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Active, not recruitingNCT06057610
Start: 2023-11-01End: 2032-10-01Updated: 2026-09-09
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
Not yet recruitingNCT07896005
Start: 2026-12-01End: 2032-03-01Target: 436Updated: 2026-10-26